Conference Details - Agenda
View all Conferences
This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy
New York Marriott Downtown
New York, NY
October 16-18, 2009
Friday, Oct 16, 2009
| 7:30 am | Registration and Continental Breakfast |
| 8:00 am | Welcome and Introductions |
| Clinical Implications of Breast Cancer Heterogeneity | |
| 8:05 am | Presession Survey |
| 8:10 am | Pathologic and Genomic Heterogeneity Philip Bernard |
| 8:40 am | ER Plasticity Rachel Schiff |
| 9:00 am | Postsession Survey |
| 9:05 am | Panel Discussion |
| 9:25 am | Break |
| Luminal Breast Cancer | |
| 9:45 am | Presession Survey |
| 9:55 am | Identification of and Targeted Therapies for High-Risk Luminal Breast Cancer Adrian V. Lee |
| 10:15 am | Which Patients With Node-Positive Disease Don't Benefit From Adjuvant Chemotherapy? Joseph A. Sparano |
| 10:35 am | Pharmacogenomics of Adjuvant Endocrine Therapy Frankie Ann Holmes |
| 10:55 am | Panel Discussion |
| 11:30 am | Lunch |
| Luminal Breast Cancer (Continued) | |
| 12:30 pm | Blocking Cross-Talk Between ER and Growth Factor Pathways Michael P. DiGiovanna |
| 12:50 am | Managing the Bone Microenvironment in Early-Stage Breast Cancer Allan Lipton |
| 1:10 pm | Postsession Survey |
| 1:20 pm | Panel Discussion |
| 1:40 pm | Break |
| HER2-Driven Breast Cancer | |
| 2:00 pm | Presession Survey |
| 2:05 pm | New Insights Into Adjuvant Therapy for HER2-Positive Breast Cancer Edward Romond |
| 2:35 pm | Endocrine Therapy in HER2-Driven Breast Cancer: Is It Effective? Rachel Schiff |
| 2:55 pm | Predicting and Overcoming Resistance to HER2-Targeted Therapy Lyndsay Harris |
| 3:15 pm | Postsession Survey |
| 3:20 pm | Panel Discussion |
| 3:45 pm | Looking Forward: Novel Targeted Therapeutic Strategies for Basal Breast Cancer Joyce O'Shaughnessy |
| 4:05 pm | Question and Answer |
| 4:15 pm | Adjourn |
Educational Grants
An educational grant for this activity was provided by:
- Genentech BioOncology
- AstraZeneca
- Novartis Oncology
- sanofi-aventis U.S.